Evaluating the Comparative Efficacy between Ivabradine and Beta Blockers in Indian Acute Coronary Syndrome Patients

The primary goal of this study was to evaluate the tolerability and efficacy between ivabradine and beta-blockers in acute coronary syndrome (ACS) patients with reduced ejection fraction and also assess the contraindications for beta-blockers. A six-month prospective observational research was carried out. The study population includes 100 patients in which Group A-50 and Group B-50. The subjects were chosen based on inclusion and exclusion criteria. The New York Heart Association (NYHA) Classification was used to categorise the patients based on their symptoms of normal breathing and varying degrees of shortness of breath. The majority of the patients were highly affected in age group between 55-64 (32%) years of age. The prevalence of ACS was high in Rural (56%). Both drugs showed decrease in the mean heart rate from 112.98±23.90 to 89.97±10.27 beats per minute in Group A and 99.6±20.44 to 86.76±13.14 beats per minute in Group B (P=0.24). The findings were clinically and statistically significant, with a standard P-value (P>0.05). Ivabradine is as effective as beta-blockers, but it has been clinically shown to lower heart rate with no negative inotropism.